Navigation Links
Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
Date:5/11/2009

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, May 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the first quarter ended March 31, 2009.

"We continue to make significant progress with both of our product candidates -- Dimebon in patients with Alzheimer's and Huntington's diseases and MDV3100 in patients with prostate cancer. Having received written permission from the FDA to initiate a pivotal Phase 3 trial of MDV3100 in castration-resistant prostate cancer, we are on track to be in Phase 3 testing in all of our clinical programs this year," said David Hung, M.D., president and chief executive officer of Medivation. "We expect to achieve a significant milestone in June - completion of enrollment in our six-month, confirmatory, pivotal Phase 3 CONNECTION trial in mild-to-moderate Alzheimer's disease. And as part of our plan to support a broad and differentiated label for Dimebon in Alzheimer's disease, we are pleased to have initiated the Phase 3 CONCERT trial of Dimebon in combination with donepezil (Aricept(R)), and intend to begin two additional Phase 3 trials in moderate-to-severe Alzheimer's disease patients this year."

Recent Highlights and Accomplishments

Dimebon

  • Expect to complete patient enrollment in CONNECTION, a confirmatory, pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, in June.
  • Initiated the Phase 3 CONCERT trial in patients with mild-to-moderate Alzheimer's disease; the 12-month clinical trial is designed to evaluate the efficacy of Dimebon when added to ongoing treatment with donepezil (Aricept(R)), the leading Alzheimer's disease medication worldwide, and builds on
    '/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (HealthDay News) -- Researchers report that children with autism ... in their brains compared with typical children. The ... the number of extra synapses through drug treatment. ... cells (neurons) connect and communicate with each other. Having ... the brain functions, theorized neuroscientists at Columbia University Medical ...
(Date:8/21/2014)... Angeles, CA (PRWEB) August 21, 2014 ... talk show “Heavy Metal Greg” will screen on Monday, ... Action on Film International Film Festival. This festival is ... several companies, including Video Symphony, Sony Software, Avid, and ... California, at Cinema 12 & LFX, located at 410 ...
(Date:8/21/2014)... and health authorities need to ensure that experimental drugs ... context of randomized controlled trials, according to a new ... 21 August, 2014]. , Leading bioethicists Professor ... and Dr Annette Rid, of King,s College London, UK, ... to if experimental drugs are to be deployed in ...
(Date:8/21/2014)... One of the emerging trends that the Intranasal ... increasing adoption of non-invasive administration products. As non-invasive nasal ... their convenient application, they find more preference among end-users. ... used for the administration of drugs for the treatment ... such as allergic and non-allergic rhinitis and sinusitis. The ...
(Date:8/21/2014)... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast, 2012 - 2018," the ... million in 2011 and is estimated to reach a ... CAGR of 6.3% from 2012 to 2018. , Browse ... , Fundus cameras market growth in recent years has ...
Breaking Medicine News(10 mins):Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:“Heavy Metal Greg,” a Music Talk Show by Gregory Graham, Will Screen at Action on Film International Film Festival on 08/25/2014 2Health News:The Lancet: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2
... Fitness Event at the Quicken Loans Arena on June 18th -- Join ... ... LeBron James and Mayor Frank Jackson,invite Cleveland residents to join a ... well-being with a FREE,health and fitness plan -- the Cleveland City Challenge. ...
... Manpower Support Cutting-Edge ... Manufacturing Activities, SAN ... a leading manufacturing hub in Asia with its strong,track record, ... output expanded,four-fold from US$4.4 billion in 2000 to US$17 billion ...
... Inc. Director of Internal Controls Adds to SAND,s ... ... SAND Technology Inc. (OTC,Bulletin Board: SNDTF), an international provider ... Schwartz,has joined the firm as Chief Financial Officer and Vice ...
... off diabetes meds and into remission, study found , , ... a major role in improving diabetes after obese patients ... , Previous studies have suggested that gastric bypass ... the stomach to the small intestine -- helps improve ...
... University of Florida department of urology officials ... German biopharmaceutical company CureVac to test an experimental ... longer respond to traditional treatment. , CureVac ... RNA, a biomolecule that transfers genetic information from ...
... over the last fifteen years in national accreditation guidelines ... a right, there is no evidence yet that this ... hospitals with chaplains. Rather, new research from Brandeis University ... Journal reports that whether hospitals had a chaplain ...
Cached Medicine News:Health News:NBA All-Star and Olympic Athlete LeBron James and Dr. Ian Smith Celebrate the Launch of The 50 Million Pound Challenge's First 'Citywide Team Challenge,' Kicking off in Cleveland, Ohio 2Health News:NBA All-Star and Olympic Athlete LeBron James and Dr. Ian Smith Celebrate the Launch of The 50 Million Pound Challenge's First 'Citywide Team Challenge,' Kicking off in Cleveland, Ohio 3Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 2Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 3Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 4Health News:SAND Technology Appoints Zainab Ahmed Schwartz as CFO 2Health News:Weight Loss After Gastric Bypass Is Key to Easing Diabetes 2Health News:UF scientists to work with German firm in prostate cancer treatment research 2Health News:When the spirit moves into the hospital 2
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... Aug. 20, 2014  The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful PSE ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,890 ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Michigan's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: